Invion Ltd (ASX: IVX) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Invion Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $7.28 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 85.65 million
Earnings per share -0.122
Dividend per share N/A
Year To Date Return -10.75%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Invion Ltd (ASX: IVX)
    Latest News

    Doctor doing a telemedicine using laptop at a medical clinic
    Share Gainers

    This small-cap ASX healthcare stock just exploded 131%! Here's why

    Investors are sending the ASX small-cap healthcare stock soaring on Tuesday.

    Read more »

    asx share price increase represented by golden dollar sign rocketing out from white domes of lithium
    Healthcare Shares

    Invion share price (ASX:IVX) rockets 123% on pilot study results

    The company's shares are rocketing to a multi-year high today.

    Read more »

    a woman
    Share Gainers

    Why the Invion share price rocketed 225% higher today

    The Invion Ltd (ASX:IVX) share price is rocketing higher on Wednesday. Here's why...

    Read more »

    a woman
    Share Gainers

    Why the Invion share price zoomed 86% higher today

    The Invion Ltd (ASX:IVX) share price almost doubled in value this morning after releasing an update on IVX-P02...

    Read more »

    a woman
    ⏸️ Investing

    Here's why Invion Ltd stock plunged 24.4% today

    Invion Ltd (ASX:IVX) is a small-cap drug developer which has lost 62% of its value since August

    Read more »

    IVX ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Invion Ltd

    Invion Ltd is an Australian clinical-stage pharmaceutical drug development company. It is engaged in the development of PhotoDynamic Therapy (PDT) for cancer treatments called Photosoft, for the treatment of a range of cancers, and infectious diseases. The company produces topical and intravenous products suitable for use in skin cancer and solid tumors, such as ovarian, prostate, and lung cancer. Invion has developed a portfolio of patent protected compounds. Its drug candidate is INV043, a novel photosensitiser which has the potential to work as a therapy and a diagnostic tool.

    IVX Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    06 Feb 2026 $0.09 $0.00 0.00% 39,449 $0.09 $0.09 $0.08
    05 Feb 2026 $0.08 $0.00 0.00% 133,080 $0.09 $0.09 $0.08
    04 Feb 2026 $0.08 $0.00 0.00% 20,723 $0.08 $0.08 $0.08
    03 Feb 2026 $0.08 $0.00 0.00% 9,416 $0.09 $0.09 $0.08
    02 Feb 2026 $0.08 $-0.01 -10.87% 325,931 $0.09 $0.09 $0.08
    28 Jan 2026 $0.09 $0.00 0.00% 92,942 $0.09 $0.09 $0.09
    27 Jan 2026 $0.09 $0.00 0.00% 482 $0.09 $0.09 $0.09
    23 Jan 2026 $0.09 $0.00 0.00% 110,368 $0.09 $0.09 $0.09
    21 Jan 2026 $0.09 $0.00 0.00% 105,227 $0.09 $0.09 $0.09
    20 Jan 2026 $0.09 $0.00 0.00% 202,617 $0.09 $0.09 $0.09
    19 Jan 2026 $0.09 $0.00 0.00% 26,704 $0.09 $0.09 $0.09
    15 Jan 2026 $0.09 $0.00 0.00% 82,957 $0.09 $0.09 $0.09
    14 Jan 2026 $0.09 $0.00 0.00% 833 $0.09 $0.09 $0.09
    13 Jan 2026 $0.09 $0.00 0.00% 72,189 $0.09 $0.09 $0.09
    12 Jan 2026 $0.09 $0.00 0.00% 48,795 $0.09 $0.09 $0.09
    09 Jan 2026 $0.09 $0.00 0.00% 2 $0.09 $0.09 $0.09

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    23 Sep 2025 Chiat Chew Expiry 1,384,886 $152,337
    Options expired.
    23 Jul 2025 Chiat Chew Issued 10,000,000 $150,000
    Rights issue.
    18 Jul 2025 Chiat Chew Issued 4,210,806 $63,162
    Rights issue.
    18 Jul 2025 Alan Yamashita Issued 115,541 $1,733
    Rights issue.
    18 Jul 2025 Alistair Bennallack Issued 181,064 $2,715
    Rights issue.
    24 Jun 2025 Alistair Bennallack Buy 37,647 $4,705
    Exercise of options.
    24 Jun 2025 Alistair Bennallack Exercise 37,647 $4,705
    Exercise of options.
    24 Jun 2025 Alan Yamashita Buy 41,411 $5,176
    Exercise of options.
    24 Jun 2025 Alan Yamashita Exercise 41,411 $5,176
    Exercise of options.
    24 Jun 2025 Chiat Chew Buy 68,086 $8,510
    Exercise of options.
    24 Jun 2025 Chiat Chew Exercise 68,086 $8,510
    Exercise of options.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Ms Melanie Jaye Leydin Non-executive directorCompany Secretary Aug 2024
    Ms Leydin is now the Executive Vice President of Global Soultions, Southeast Asia at Vistra. Vistra is a provider of governance and compliance solutions and finance and accounting solutions in the Fund, Corporate, Capital Markets, and Private Wealth sectors. Melanie has over 20 years of experience holding Board positions including Company Secretary and CFO of ASX listed entities. Melanie has experience in relation to public company responsibilities, including ASX and ASIC compliance, control and implementation of corporate governance, statutory financial reporting, reorganization of Companies, initial public offerings, secondary raisings and shareholder relations.
    Mr Chiat Thian Chew Chief Executive OfficerExecutive ChairmanExecutive Director Dec 2017
    Mr Chew has over 25 years of experience in healthcare biotech, investing and transforming business operations. He is also Co-Founder of Chronic Airway Therapeutics; a clinical stage firm focused on the treatment of respiratory diseases and Managing Partner at Polar Ventures. Thian is also an Advisory Board Member at Stanford Medicine's Center for Asian Health Research and Education (CARE). Prior to this, Thian was an Executive Director at Goldman Sachs (New York, Hong Kong), responsible for the firm's proprietary investments, and was a Consultant Project Manager at Morgan Stanley's Strategic Services Group (New York). He also held several positions in KPMG across Asia Pacific including Director at KPMG Consulting (Singapore and Sydney) where he led several large-scale operational restructurings, post-merger integration, transformation, and business performance improvement programs. As a Senior Manager at KPMG (Taipei and Melbourne), he led several business re-engineering initiatives, and performed financial and information technology audit, risk and assurance engagements across multiple industries. He is also Visiting Professor at UCL Global Business School for Health.
    Mr Alan Yamashita Non-Executive Director Feb 2019
    Mr Yamashita is an experienced corporate consultant and investment professional, with over 40 years of experience in investment management, investment banking and alternative investment throughout the APAC region. From 1999 to 2005, Mr Yamashita was President and CEO of Search Investment Group and founding CEO and CIO of Search Alternative Investment Ltd (SAIL), a private global hedge fund and private equity investment practice headquartered in Asia. Prior to Search Investments Group, Mr Yamashita was Managing Director and Head of Asia Capital Markets for Merrill Lynch from 1996 to 1998. Mr Yamashita is currently Managing Partner at Polar Ventures and has held numerous positions as a 16-year veteran of Goldman Sachs and an advisor to various companies, including Plantation Timber Partners, Wuhan; Duty Free Shoppers, Asia; TVSN, Shanghai; and Mizuho Alternative Investments LLC. He is a Member of the Risk Committee.
    Mr Alistair Bennallack Non-Executive Director Oct 2020
    Mr Bennallack is currently the Chief Operating Officer and Chief Financial Officer of Village Roadshow Pty Ltd. In this capacity he also has primary responsibility for the Group Risk function. In addition, he is also Chief Executive Officer of Village Roadshow Theme Parks Asia, a division of Village Roadshow Theme Parks Pty Ltd. He is the primary executive responsible for conceptualizing, executing and delivering Village Roadshow's expansion into China and Asia. He is a former member of the Village Roadshow Ltd Executive Committee, current member of the Village Roadshow Theme Parks Executive Committee and current member of all Village Roadshow Pty Ltd's Management and Risk Committees. His previous roles have included Chief Financial Officer of Village Roadshow Ltd and General Manager Business Affairs of Village Roadshow Corporation Pty Ltd (controlling shareholder of Village Roadshow Ltd.). He is Chair of the Risk Committee.

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Polar Ventures Limited 5,452,178 8.20%
    BNP Paribas Nominees Pty Noms Retail Client Drp> 5,447,343 8.00%
    RMWC Pty Ltd Rmwc Family A/C> 3,142,372 4.70%
    Surfit Capital Pty Ltd 3,000,000 4.30%
    Mr Honsue Cho 2,846,265 4.10%
    Ngpdt Greater China Limited 2,726,523 4.10%
    Mei Jun Lin 2,725,000 3.40%
    Citicorp Nominees Pty Limited 2,468,145 3.00%
    Ms Xiaoyi Wu Xiaoyi Wu Interactive Brokers A/C> 2,000,000 2.70%
    Acslnc Pty Ltd Acslnc Family A/C> 1,928,000 2.70%
    Shengli Wang 1,362,881 2.30%
    Ms Xiaoyi Wu Xiaoyi Wu Interactive Brokers A/C> i 1,214,286 2.10%
    Yong Chen 1,100,000 1.80%
    Mr Yong Chen 932,531 1.70%
    Zanya Nominees Pty Ltd Jls Superannuation A/C> 917,744 1.40%
    Ms Dandan Wang 828,196 1.20%
    Mr Shengwei Ou 773,042 1.20%
    Shubo Miao 733,334 1.10%
    Hunt Prosperity Pty Ltd Investius Pb Micro A/C> 714,286 1.00%
    Mr Esmond Wong & Mrs Quynh Thi Kim Nguyen 675,648 0.90%

    Profile

    since

    Note